Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheap steroid could save lives from hospital lung infections

NCT ID NCT05354778

Disease control Sponsor: Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether the steroid hydrocortisone, added to usual care, can help ICU patients with severe hospital-acquired pneumonia. Researchers will compare hydrocortisone against a placebo in 180 adults. The goal is to see if the drug reduces early death or worsening of breathing and heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hydrocortisone (a corticosteroid)
What this could lead to
If it works, this could provide a cheap, widely available treatment to reduce deaths from hospital-acquired pneumonia in intensive care.
What could go wrong
This is an early-stage trial with only 180 patients, so results may not apply to everyone. Corticosteroids also carry risks like infection or blood sugar problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

180 people

The number who actually took part.

Started

Oct 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Suspected ou confirmed case of bacterial nosocomial pneumonia (including ventilator-associated pneumonia) * Intensive Care Unit stay * Signed consent form (by the patient or a legal guardian) Exclusion Criteria: * Women who are pregnant, have recently given birth or are breastfeeding * Patients who are moribund or do not have a treatment perspective * Patients with community acquired pneumonia * Patients with other types of pneumonia (viral - including COVID-19, fungal etc.) * Those with pulmonary infiltrates in chest image which are not compatible with bacterial pneumonia * Patients with adrenal insufficiency * Patients who have a condition that demands the use of corticosteroids (acute or chronic) * Patients allergic to hydrocortisone * Patients with refractory septic shock (those receiving more than 0,5mcg/kg/min of norepinephrine)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthcare-associated pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Healthcare-Associated Pneumonia nosocomial infection pneumonia Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthcare-associated pneumonia Ventilator associated pneumonia

Contacts and locations

Locations

  • Hospital do Servidor Publico Estadual

    São Paulo, Sao Paulo SP, 04039-901, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.